4.8 Article

Cancer cell-intrinsic XBP1 drives immunosuppressive reprogramming of intratumoral myeloid cells by promoting cholesterol production

Journal

CELL METABOLISM
Volume 34, Issue 12, Pages 2018-+

Publisher

CELL PRESS
DOI: 10.1016/j.cmet.2022.10.010

Keywords

-

Funding

  1. National Key R&D Program of China [2017YFA0506400]
  2. Strategic Priority Research Program of CAS [XDB37020305]
  3. National Natural Science Foundation of China [31900564, 91754105, 31770877, 32170785]

Ask authors/readers for more resources

A hostile microenvironment in tumor tissues disrupts endoplasmic reticulum homeostasis and activates the unfolded protein response. The UPR component X-box binding protein 1 (XBP1) in cancer cells promotes the synthesis and secretion of cholesterol, which activates myeloid-derived suppressor cells (MDSCs) and causes immunosuppression. Inhibition of XBP1 or reduction of tumor cholesterol content significantly reduces MDSC abundance and triggers robust anti-tumor responses.
A hostile microenvironment in tumor tissues disrupts endoplasmic reticulum homeostasis and induces the unfolded protein response (UPR). A chronic UPR in both cancer cells and tumor-infiltrating leukocytes could facilitate the evasion of immune surveillance. However, how the UPR in cancer cells cripples the anti-tumor immune response is unclear. Here, we demonstrate that, in cancer cells, the UPR component X-box binding protein 1 (XBP1) favors the synthesis and secretion of cholesterol, which activates myeloid-derived suppres-sor cells (MDSCs) and causes immunosuppression. Cholesterol is delivered in the form of small extracellular vesicles and internalized by MDSCs through macropinocytosis. Genetic or pharmacological depletion of XBP1 or reducing the tumor cholesterol content remarkably decreases MDSC abundance and triggers robust anti-tumor responses. Thus, our data unravel the cell-non-autonomous role of XBP1/cholesterol signaling in the regulation of tumor growth and suggest its inhibition as a useful strategy for improving the efficacy of can-cer immunotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available